@article{Liu2022, 
author = {Hongmei Liu and Ding Ma and Jinpeng Chen and Li Ye and Yiping Li and Yuexia Xie and Xue Zhao and Hanbing Zou and Xiaojing Chen and Jun Pu and Peifeng Liu},
title = {A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer},
year = {2022},
journal = {Nano Research},
volume = {15},
number = {7},
pages = {6306-6314},
keywords = {multi-drug resistance (MDR), breast cancer, adenosine triphosphate (ATP) responsiveness, ε-polylysine},
url = {https://www.sciopen.com/article/10.1007/s12274-022-4254-1},
doi = {10.1007/s12274-022-4254-1},
abstract = {Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer patients receiving traditional chemotherapeutics or novel targeted drugs. Here, we developed a targeted nanoplatform based on biodegradable boronic acid modified ε-polylysine to co-deliver P-gp siRNA, Bcl-2 siRNA, and doxorubicin for overcoming the challenge. The targeted nanoplatform showed a robust suppressing efficiency for the invasion, proliferation, and colony formation of adriamycin (ADR) resistant breast cancer cell line (MCF-7/ADR) cells in vitro. The ATP responsiveness of the nanoplatform was also proved in the research. In thein vivo antitumor experiment, the targeted nanoplatform showed a significant inhibition of tumor growth with good biocompatibility. The goal of this study is to develop a novel and facile strategy to prepare a highly efficient and safe gene and drug delivery system for MDR breast cancer based on biocompatible ε-polylysine polymers.}
}